Merck & Premier Inc. join hands to reduce C. diff recurrence
Category: #health  By Saipriya Iyer  Date: 2018-06-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck & Premier Inc. join hands to reduce C. diff recurrence

Merck & Co., a U.S. based pharmaceutical giant, and Premier Inc., have reportedly extended their partnership on preventative & chronic ailment care for minimizing the recurrence of the Clostridium difficile infection. Sources cite that both the Merck and Premier are expected to offer support, education, and consultation to patients suffering from C. diff.

The strategic move is aimed at increasing the awareness level of the patients for reducing the recurrence of the infectious ailment and facilitating easy access of healthcare services for the patients. For the record, both the healthcare firms have been carrying out research activities for preventing the disease recurrence in the subjects.

According to CDC (Centers for Disease Control and Prevention), the elaborate use of antibiotic medicines or long-term C. diff infection is one of the main causes of healthcare-related infections across the U.S. Estimates claim that nearly half a million of the U.S. population are affected due to the infection, with patients consuming antibiotics more prone to get infected from the ailment.

C.diff accounts for nearly USD 4.8 billion of the country’s healthcare expenditure each year. Data statistics have revealed that one out of five patients experience the recurrence of the disease.

Raquel Tapia, Associate Vice President of Specialty Marketing at Merck, has announced that the integration of Premier Inc.’s tech abilities and therapeutic knowledge of Merck will help the patients effectively handle their healthcare challenges. Reportedly, the C. diff intervention is projected to be tested at the Premier member health systems.

It has been predicted that the extension of the business relationships will make a big difference in resolving the critical public health issues of the patients across the globe.

For the uninitiated, Premier Inc., is one of the leading healthcare improvement companies that encompasses close to 3,900 U.S. hospitals and health systems in addition to a mammoth 150,000 other providers.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

CTI-Medidata partner to adopt Remote Source Review in clinical trials
CTI-Medidata partner to adopt Remote Source Review in clinical trials
By Saipriya Iyer

CTI Clinical Trial and Consulting Services will reportedly adopt Remote Source Review of Medidata. Medidata is the end-to-end solutions provider to support the clinical trials. This contract research organization will ...

NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
By Saipriya Iyer

Nizam’s Institute of Medical Science (NIMS) has recently commenced the enrollment of subjects for its Phase 1 clinical trials of the COVID-19 vaccine. It is the 1st indigenous coronavirus vaccine candidate develo...

Walmart to compete Amazon Prime with new subscription service, Walmart
Walmart to compete Amazon Prime with new subscription service, Walmart
By Saipriya Iyer

U.S retail giant, Walmart Inc. has recently joined the race against Amazon with its latest subscription service, Walmart+. Similar to Amazon Prime, the new subscription service will endow Walmart customers wi...